AC Immune SA (NASDAQ:ACIU) Sees Significant Increase in Short Interest

AC Immune SA (NASDAQ:ACIU) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 984,500 shares, an increase of 23.5% from the October 15th total of 796,900 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily volume of 92,100 shares, the days-to-cover ratio is presently 10.7 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its position in AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of AC Immune during the first quarter worth $30,000. Redmile Group LLC increased its holdings in shares of AC Immune by 0.4% during the first quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after buying an additional 7,031 shares in the last quarter. Silverberg Bernstein Capital Management LLC bought a new position in shares of AC Immune in the 2nd quarter valued at $40,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after acquiring an additional 328,312 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AC Immune in a report on Friday.

AC Immune Stock Down 10.1 %

Shares of ACIU stock opened at $3.19 on Friday. The business has a fifty day simple moving average of $3.28 and a 200 day simple moving average of $3.49. The company has a market cap of $315.62 million, a P/E ratio of -6.93 and a beta of 1.28. AC Immune has a twelve month low of $2.25 and a twelve month high of $5.14.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.